Completed PHASE4 INTERVENTIONAL 4-arm NCT00293228

Treatment of Latent Tuberculosis Infection With Isoniazid

Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB

Sponsor: Bill and Melinda Gates Foundation

Conditions Tuberculosis

Interventions Isoniazid isoniazid

Updated 5 times since 2017 Last updated: May 25, 2010 Started: Feb 28, 2007 Primary completion: Mar 31, 2008 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00293228, this PHASE4 trial focuses on Tuberculosis and remains completed. Sponsored by Bill and Melinda Gates Foundation, it has been updated 5 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bill and Melinda Gates Foundation
Instituto Nacional de Salud Publica, Mexico
Wellcome Trust

Data source: Instituto Nacional de Salud Publica, Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cuernavaca, Mexico